The vaccine can be stored at 2 to 8-degree centigrade
The National Agency for Food and Drug Administration and Control (NAFDAC) has approved the use of AstraZeneca’s COVID-19 vaccine for the treatment and prevention of COVID-19 in Nigeria out of the four vaccines sent by the Health ministry a week ago for evaluation.
This came after the announcement by the Minister of Health Osagie Enahire disclosed that the agency has been given four dossiers for Sputnik V vaccine of Russia, Covishield or Astra Zeneca manufactured under license by Serum Institute of India, Covaxin by Bharat vaccines of India, and the Sinopharm Vaccine of China, for evaluation and validation for use in Nigeria.
The Director-General of NAFDAC, DR. Mojisola Adeyeye disclosed that the evaluation on AstraZeneca showed that it can be stored at 2 to 8 degrees centigrade and the vaccine is effective against the UK variant of the virus which has been reported in Nigeria.
She said that the agency got the dossier of the vaccine a week ago and it went to work immediately to evaluate its efficacy. She also disclosed that the South African variant of the virus has not been reported in Nigeria.
Oxford/AstraZeneca vaccine, also known as ChAdOx1 nCoV-19, or AZD1222, is a viral vector vaccine. Scientists used an adenovirus, originally derived from chimpanzees, and modified it with the aim of training the immune system to mount a strong response against SARS-CoV-2 (the virus that causes COVID-19).